At the end of the day, whether RAP succeed all hinges on the regulatory approval for their algorithm but it's another "decision" by management that shows they don't deserve their 94M performance share options.....to me it's sounds like Avanti Med will actually be a subsidiary of RAP (who will involve to a biotech/tech and device manufacturer, hence, "partnership").
Ann: Market Clarification Announcement, page-70
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)